Stockscreener 앱 받기
2.84
0.35%
-0.01
전일 마감가:
$2.85
열려 있는:
$2.68
하루 거래량:
66,142
Relative Volume:
2.51
시가총액:
$19.82M
수익:
-
순이익/손실:
-
주가수익비율:
-3.521
EPS:
-0.8066
순현금흐름:
-
1주 성능:
+12.70%
1개월 성능:
+18.33%
6개월 성능:
-4.70%
1년 성능:
+16.83%
1일 변동 폭
$2.665
$3.12
1주일 범위
$2.48
$3.12
52주 변동 폭
$2.0001
$3.89
Neuraxis Inc Stock (NRXS) Company Profile
명칭
Neuraxis Inc
전화
(812) 689-0791
주소
11550 North Meridian Street, Suite 325, Carmel
NRXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.84 | 19.82M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neuraxis Inc 주식(NRXS)의 최신 뉴스
NeurAxis, Inc. Announces New Medical Policy Coverage with a Prominent Insurer for over Five Million Lives Across Multiple States - Marketscreener.com
UPDATENeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States - The Manila Times
NeurAxis Expands IBS Treatment Coverage to 51M Lives, Targets Youth Market with Novel Device - StockTitan
NeurAxis Announces New Medical Policy Coverage with Molina - GlobeNewswire
NeurAxis Expands Coverage for FDA-Cleared IBS Pain Device to 51M Lives with Molina Deal - StockTitan
NeurAxis announces Q4 preliminary unaudited revenues were about $800 thousand - MSN
Vagus Nerve Stimulators Market Growth in Future Scope 2025-2032 - openPR
Critical Analysis: Precision Optics (NASDAQ:POCI) & NeurAxis (NASDAQ:NRXS) - Defense World
Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors - The Manila Times
NeurAxis Inc. Issues Letter to Shareholders - GlobeNewswire
NeurAxis IB-Stim Reaches Major Milestone: Insurance Coverage Surges to 51 Million Lives, FDA Expands Age Range - StockTitan
NeurAxis, Inc. Reports Strong Preliminary Unaudited Fourth Quarter 2024 Results - Defense World
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year - Marketscreener.com
Everything Blockchain Inc. Announces Letter to Shareholders from CEO - The Manila Times
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth - GlobeNewswire
NeurAxis Q4 Revenue Surges 50% as IB-Stim Coverage Reaches 45 Million Lives - StockTitan
NeurAxis (NASDAQ:NRXS) Shares Down 4.1% – What’s Next? - Defense World
Model N Appoints New Chief Executive Officer, Bret Connor - The Manila Times
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - GlobeNewswire
NeurAxis CEO to Present at Lytham Partners 2025 Healthcare Investor Summit - StockTitan
MicroCap Opportunities 2024 Year-End Portfolio Update - substack.com
FDA Approvals News Live Feed - StockTitan
Vagus Nerve Stimulators Market Growth in Future Scope 2024-2031 - openPR
NeurAxis (NASDAQ:NRXS) Stock Price Down 5.3% – Here’s What Happened - Defense World
NeurAxis Inc. Announces FDA 510(k) Clearance of Red for Testing and Evaluation of Patients with Chronic Constipation - Marketscreener.com
Connyct Launches on iOS: Build Your College Crew, Share Your Vibe, and Never Miss a Party - The Manila Times
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for - GlobeNewswire
NeurAxis Secures FDA Clearance for Revolutionary Chronic Constipation Testing Device - StockTitan
FDA Awards New Clearance to NeurAxis’ IB-Stim - MPO-mag
Rosalind Advisors, Inc. Acquires Significant Stake in Neuraxis I - GuruFocus.com
Neuraxis increases Series B Preferred Stock and extends dividend rights By Investing.com - Investing.com South Africa
Neuraxis increases Series B Preferred Stock and extends dividend rights - Investing.com
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage - MSN
Critical Review: BioSig Technologies (NASDAQ:BSGM) vs. NeurAxis (NASDAQ:NRXS) - Defense World
NeurAxis, Inc. (NASDAQ:NRXS) Q3 2024 Earnings Call Transcript - MSN
Neuraxis secures $5 million in preferred stock sale By Investing.com - Investing.com Nigeria
Neuraxis secures $5 million in preferred stock sale - Investing.com
Neuronetics Grants Inducement Awards to New Employees - MSN
NeurAxis Stock Surges After Strong Q3 Earnings And Expanded Coverage - Barchart
Neuraxis Inc. (NRXS) Quarterly 10-Q Report - Quartz
NeurAxis reports 40% increase in revenues in Q3 2024 - Medical Buyer
NeurAxis Reports Strong Revenue Growth in Q3 2024 - TipRanks
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues - GlobeNewswire
NeurAxis Q3 Revenue Surges 40%, Expands Coverage to 35M Lives Amid FDA Milestone | NRXS Stock News - StockTitan
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market - Building Indiana
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024 - GlobeNewswire
Neuraxis Inc (NRXS) 재무 분석
Neuraxis Inc (NRXS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):